Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30374480 | 1.00 | CYP11B1 (0.35) | CYP11B1CYP11B2S1PR1HSD11B1S1PR3 | |
| SCHEMBL21719110 | 0.80 | GABRA1 (0.30) | — | |
| SCHEMBL723605 | 0.75 | — | — | |
| SCHEMBL25584913 | 0.74 | CYP11B1 (0.33) | CYP11B1CYP11B2S1PR1HSD11B1 | |
| SCHEMBL3782535 | 0.74 | CYP11B1 (0.35) | CYP11B1CYP11B2HSD11B1 | |
| SCHEMBL16127380 | 0.74 | CYP11B2 (0.37) | CYP11B1CYP11B2HSD11B1 | |
| Hydrochloric Acid SCHEMBL18189392 | 0.73 | UHRF1 (0.35) | — | |
| SCHEMBL23620109 | 0.71 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL21938071 | 0.71 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL25584915 | 0.69 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313212-B | OGA inhibitor compounds | 詹森药业有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-05-06 | — | — | US | disclosed |
| EP-3810586-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112313212-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019243533-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CYP11B1 4512/4885CYP11B2 4635/4885S1PR1 4514/4885 |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CYP11B1 4512/4885CYP11B2 4635/4885S1PR1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.